Midatech is a clinical stage biotechnology company dedicated to translating its proprietary gold nanoparticle (GNP) drug delivery platform into efficacious nanomedicines targeting unmet medical need. With flexibility in all parameters and less than 3.5 nanometers in size, Midatech’s pipeline of passivated GNPs is poised to improve the delivery and efficacy of existing drugs while decreasing limiting side effects.

The Company’s corporate  headquarters are  in Oxford, UK. It also has two wholly owned subsidiaries: Pharmida AG, Switzerland  for Drug Development and Midatech Biogune S.L., Spain for Manufacturing as well as Business Development, Partnering and Licensing support in Europe and the USA.